These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
575 related items for PubMed ID: 10911006
21. Nesiritide for decompensated congestive heart failure. Med Lett Drugs Ther; 2001 Nov 12; 43(1118):100-1. PubMed ID: 11707752 [No Abstract] [Full Text] [Related]
22. Nesiritide: past, present, and future. Burger AJ, Burger MR. Minerva Cardioangiol; 2005 Dec 12; 53(6):509-22. PubMed ID: 16333235 [Abstract] [Full Text] [Related]
23. Observation unit treatment of heart failure with nesiritide: results from the proaction trial. Peacock WF, Holland R, Gyarmathy R, Dunbar L, Klapholz M, Horton DP, de Lissovoy G, Emerman CL. J Emerg Med; 2005 Oct 12; 29(3):243-52. PubMed ID: 16183441 [Abstract] [Full Text] [Related]
24. BNP in decompensated heart failure: diagnostic, prognostic and therapeutic potential. Burger MR, Burger AJ. Curr Opin Investig Drugs; 2001 Jul 12; 2(7):929-35. PubMed ID: 11757793 [Abstract] [Full Text] [Related]
25. Renal effects of ularitide in patients with decompensated heart failure. Lüss H, Mitrovic V, Seferovic PM, Simeunovic D, Ristić AD, Moiseyev VS, Forssmann WG, Hamdy AM, Meyer M. Am Heart J; 2008 Jun 12; 155(6):1012.e1-8. PubMed ID: 18513512 [Abstract] [Full Text] [Related]
26. Assessment of dyspnea in acute decompensated heart failure: insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow. Ezekowitz JA, Hernandez AF, O'Connor CM, Starling RC, Proulx G, Weiss MH, Bakal JA, Califf RM, McMurray JJ, Armstrong PW. J Am Coll Cardiol; 2012 Apr 17; 59(16):1441-8. PubMed ID: 22497823 [Abstract] [Full Text] [Related]
27. Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide. Kurien S, Warfield KT, Wood CM, Miller WL. Am J Cardiol; 2006 Dec 15; 98(12):1627-30. PubMed ID: 17145223 [Abstract] [Full Text] [Related]
28. Effect of nesiritide infusion duration on renal function in acutely decompensated heart failure patients. Chow SL, Peng JT, Okamoto MP, Heywood JT. Ann Pharmacother; 2007 Apr 15; 41(4):556-61. PubMed ID: 17389662 [Abstract] [Full Text] [Related]
29. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. Mills RM, LeJemtel TH, Horton DP, Liang C, Lang R, Silver MA, Lui C, Chatterjee K. J Am Coll Cardiol; 1999 Jul 15; 34(1):155-62. PubMed ID: 10400005 [Abstract] [Full Text] [Related]
30. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP. N Engl J Med; 1993 Jul 15; 329(3):149-55. PubMed ID: 8515787 [Abstract] [Full Text] [Related]
31. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial. Follath F. Ital Heart J; 2003 May 15; 4 Suppl 2():34S-38S. PubMed ID: 14635368 [Abstract] [Full Text] [Related]
32. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure. Arnold LM, Crouch MA, Carroll NV, Oinonen MJ. Pharmacotherapy; 2006 Aug 15; 26(8):1078-85. PubMed ID: 16863484 [Abstract] [Full Text] [Related]
33. The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure. Schalcher C, Cotter G, Reisin L, Bertel O, Kobrin I, Guyene TT, Kiowski W. Am Heart J; 2001 Aug 15; 142(2):340-9. PubMed ID: 11479476 [Abstract] [Full Text] [Related]
34. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. Khot UN, Novaro GM, Popović ZB, Mills RM, Thomas JD, Tuzcu EM, Hammer D, Nissen SE, Francis GS. N Engl J Med; 2003 May 01; 348(18):1756-63. PubMed ID: 12724481 [Abstract] [Full Text] [Related]
35. Acute hemodynamic effects of intravenous nesiritide on left ventricular diastolic function in heart failure patients. Efstratiadis S, Michaels AD. J Card Fail; 2009 Oct 01; 15(8):673-80. PubMed ID: 19786256 [Abstract] [Full Text] [Related]
36. Pharmacodynamic effects of milrinone with and without a bolus loading infusion. Baruch L, Patacsil P, Hameed A, Pina I, Loh E. Am Heart J; 2001 Feb 01; 141(2):266-73. PubMed ID: 11174341 [Abstract] [Full Text] [Related]
37. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Burger AJ, Elkayam U, Neibaur MT, Haught H, Ghali J, Horton DP, Aronson D. Am J Cardiol; 2001 Jul 01; 88(1):35-9. PubMed ID: 11423055 [Abstract] [Full Text] [Related]
38. Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure). Gottlieb SS, Stebbins A, Voors AA, Hasselblad V, Ezekowitz JA, Califf RM, O'Connor CM, Starling RC, Hernandez AF. J Am Coll Cardiol; 2013 Sep 24; 62(13):1177-83. PubMed ID: 23747790 [Abstract] [Full Text] [Related]
39. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML. N Engl J Med; 1991 Nov 21; 325(21):1468-75. PubMed ID: 1944425 [Abstract] [Full Text] [Related]
40. How to use nesiritide in treating decompensated heart failure. Mills RM, Hobbs RE. Cleve Clin J Med; 2002 Mar 21; 69(3):252-6. PubMed ID: 11890216 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]